Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (196)	11/5/1998 9:25:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 523

biz.yahoo.com Neurogen and Pfizer Extend and Expand GABA Drug Research: Depression Added to Programs for Anxiety, Insomnia and Memory Disorders Collaboration Ranks Among Longest in the Industry BRANFORD, Conn., Nov. 5 /PRNewswire/ -- Neurogen Corporation (Nasdaq: NRGN - news) today announced a $12.5 million two year extension of its long-standing collaborations with Pfizer Inc. [NYSE:PFE - news] covering GABA neurotransmitter receptor based drug programs for the treatment of anxiety, sleep disorders, and cognition enhancement. The extension agreement also expands the scope of Neurogen/Pfizer joint efforts in GABA by including depression as a new target indication. It will provide Neurogen $6.24 million per year in added funded research payments in both 1999 and 2000. (snip)